This trial is evaluating whether Autologous TriCAR T-cells and lymphodepletion chemotherapy will improve 1 primary outcome in patients with Leukemia, B-Cell. Measurement will happen over the course of within 28 days of the TriCAR T cell infusion..
This trial requires 38 total participants across 1 different treatment group
This trial involves a single treatment. Autologous TriCAR T-cells And Lymphodepletion Chemotherapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"In patients with life-threatening symptomatic disease, it is important that patients and physicians discuss potential benefits and risks of clinical trial participation before deciding to enroll in a clinical trial. Patients who are considering clinical trial participation should carefully evaluate whether the proposed treatment appears to provide meaningful survival benefit in their own situation." - Anonymous Online Contributor
"No definitive evidence exists to suggest that any cancer can be cured. However, recent advances in chemotherapy and immunotherapy offer hope for long-term survival in patients with ALL treated according to current clinical protocols. Patients with newly diagnosed ALL should receive a full evaluation to determine prognosis and direct therapy accordingly. A patient's age at diagnosis and response to initial chemotherapy predicts eventual outcome." - Anonymous Online Contributor
"Autologous T-cell depletion with CD34+ selection before allogeneic T-cell infusion was associated with improved clinical outcomes in patients with relapsed/refractory B-cell chronic lymphocytic leukemia. ClinicalTrials.gov Identifier: NCT00536682." - Anonymous Online Contributor
"The most commonly used treatments for leukemia include chemotherapy and radiation therapy. However, many patients respond well to combinations of drugs, including anthracyclines, taxanes, proteasome inhibitors, immunomodulators, alkylating agents, cyclo-oxygenase inhibitors, and antimetabolites. This article focuses on four chemotherapy regimens used to treat acute myeloid leukemia.\n\nIn 1955, César Milstein, Edward B. Schramm, and Paul Gerson developed a method for isolating antibodies against foreign proteins called hybridomas." - Anonymous Online Contributor
"Leukemia is a life threatening disease where timely diagnosis and optimal treatment are critical. Most patients with AML will relapse despite intensive therapy. People who have had leukemia should be advised to maintain a low-fat diet to reduce their risk of developing secondary cancers. Some people with AML will die within a year of diagnosis. The average survival time after diagnosis is only 10 months. Patients with ALL have improved outcomes today because they receive aggressive therapy for longer periods of time than before and because new treatments that target ALL have been developed. However, most children with ALL must undergo painful and risky procedures such as bone marrow transplantation. They also face a high rate of relapse and death within 5 years of diagnosis." - Anonymous Online Contributor
"Findings from a recent study demonstrates the need for improved data collection and dissemination of information regarding the incidence and mortality rates of leukemia. If the incidence and mortality rate are higher than what has been reported by Medicare and state-based Medicaid programs, this may indicate that these programs do not adequately cover patients with leukemia." - Anonymous Online Contributor
"Autologous T-cell transplantation followed by lymphodepletion therapy was well tolerated and highly effective in patients with relapsed/refractory AL/AML. Longer follow up is needed to assess whether these results translate into improved outcome." - Anonymous Online Contributor
"This disease occurs mostly in middle-aged adults; however, it also affects children and the elderly. The overall median age of diagnosis was 57 years old with a male-to-female ratio of 1.1:1." - Anonymous Online Contributor
"Autologous T-cell transplantation appears to improve QOL in patients with chronic myelogenous leukemia and acute lymphocytic leukemia. Findings from a recent study supports the use of autologous T-cell transplantation as an alternative treatment strategy in leukemia." - Anonymous Online Contributor
"This is the first clinical trial evaluating the use of autologous T cells in patients with relapsed/refractory non-Hodgkin Lymphoma. Results from a recent clinical trial suggest that this approach may provide an additional therapeutic role in certain groups of patients with refractory NHL." - Anonymous Online Contributor